Verastem

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced a mini oral presentation highlighting updated data from the ongoing investigator-sponsored Phase 1/2 FRAME study. The FRAME study, led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, is investigating VS-6766, Verastem's RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in

Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021

Aprea Therapeutics

Capricor Therapeutics

ConforMIS

Spectrum Pharma

Penny stocks with important dates to know this week. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 5 To Watch This Week With Biotech Catalysts

Hepion Pharmaceuticals Inc

Leap Therapeutics

Nymox Pharmaceutical

These penny stocks have upcoming events you should know about. The post 4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351%

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that management will present virtually at the following upcoming investor conferences: H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13, 2021 at 7:00 a.m. Eastern Time Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 4:00 p.m. Eastern Time A webcast of the presentation

Verastem Oncology to Present at Upcoming Investor Conferences

NexGen Energy

PetVivo Holdings

Seanergy Maritime Hlds

These Reddit penny stocks popped off today, are they worth watching in 2021 The post These Reddit Penny Stocks Exploded Today, Are They On Your List? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

These Reddit Penny Stocks Exploded Today, Are They On Your List?

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today reported financial results for the three months ended June 30, 2021 and highlighted recent progress. “There were several achievements of note during the second quarter, specifically the receipt of Breakthrough Therapy designation for VS-6766 in combination with defactinib for the treatment of recurrent low-grade serous ovarian cancer. Up

Verastem Oncology Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that an abstract detailing updated results from the ongoing Phase 1/2 FRAME study investigating VS-6766, the Company's RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in patients with low grade serous ovarian cancer (LGSOC) has been selected for a mini oral presentation at the upcoming European Society of

Verastem Oncology Announces Updated Phase 1/2 FRAME Study Data in Low Grade Serous Ovarian Cancer Selected for a Mini Oral Presentation at the European Society of Medical Oncology Congress 2021

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that it has converted all of the $28.0 million aggregate principal of the Company's 2020 5.00% Convertible Senior Notes due 2048 (the 2020 Notes) in exchange for approximately 8.6 million shares of the Company's common stock, based on the Company's existing Mandatory Conversion right. This transaction, which eliminates substant

Verastem Oncology Announces Conversion of Senior Notes Eliminating Substantially All Outstanding Debt

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced the appointments of Paul Bunn, M.D., and Lesley Solomon to its Board of Directors, adding additional strength in the areas of academic research and business innovation. Dr. Bunn, a Distinguished Professor of Medicine and James Dudley Chair in Cancer Research, Division of Medical Oncology at the University of

Verastem Oncology Appoints Paul Bunn, M.D., and Lesley Solomon to Board of Directors

Verastem: Catalyst Desert Looms

Adaptimmune Therapeutics

These unloved cancer stocks should dramatically outperform Dogecoin over the long haul.

2 Biotech Penny Stocks That Are Vastly Superior Investments to Dogecoin

Verastem (VSTM) has moved higher as of late, but there could definitely be trouble on the horizon for this company.

Verastem (VSTM) Enters Overbought Territory

Safe Bulkers

Tellurian

Did these penny stocks slip by yesterday unnoticed? Here's 3 big gainers you may have missed The post These Penny Stocks Hit it Big Yesterday, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

These Penny Stocks Hit it Big Yesterday, Here's Why

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq: VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present at the 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:00 p.m. ET. A live webcast of the presentation will be available on the investors section of the Company's website at www.verastem.com. An archived presentation will be available for 30

Verastem Oncology to Present at the 2021 Jefferies Virtual Healthcare Conference

The biotech's experimental cancer treatment won an important regulatory designation today.

Why Verastem Stock Is Crushing It Today

The stock price of Verastem Inc (NASDAQ: VSTM) increased by over 20% during intraday trading. This is why it happened.

VSTM Stock Price: Over 20% Increase Explanation

The FDA has granted Breakthrough Therapy designation to Verastem Inc (NASDAQ: VSTM) for the combination of its investigational VS-6766, with defactinib, for recurrent low-grade serous ovarian cancer (LGSOC) regardless of KRAS status after one or more prior lines of therapy, including platinum-based chemotherapy. The combination is being evaluated in the Phase 1/2 FRAME trial.

Verastem's VS-6766/Defactinib Combo Gets Breakthrough Therapy Tag For Ovarian Cancer; BTIG Upgrades Stock

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for the combination of its investigational RAF/MEK inhibitor VS-6766, with defactinib, its FAK inhibitor, for the treatment of all patients with recurrent low-grade serous ovarian cancer (LGSOC) regardless of

Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq: VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today reported financial results for the three months ended March 31, 2021, highlighted recent progress and outlined key corporate objectives. “During the first quarter of 2021, we expanded the selection portion of the Phase 2 RAMP 201 study to include all recurrent low-grade serous ovarian cancer types. This dec

Verastem Oncology Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress

ADMA Biologics

Boxlight

Penny stocks are back in a big way; which 3 should you watch? The post Penny Stocks Are Back; Here's 3 to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks Are Back; Here's 3 to Watch Right Now

Verastem monetised its approved asset Copiktra and now has a decent cash runway. Last year, it acquired new assets that it is running through trials.

Verastem: New Assets, New Indications

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq: VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today reported financial results for the three months and full year ending December 31, 2020, and highlighted its key corporate objectives for 2021 and early 2022. “We are encouraged as we continue to gain greater understanding of the profile of our RAF/MEK inhibitor VS-6766 and its role in blocking multiple node

Verastem Oncology Reports Fourth Quarter and Full Year 2020 Financial Results, Clinical Updates and Guidance for Key Milestones in 2021 and 1H 2022

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will participate in the virtual H.C. Wainwright Global Life Sciences Conference. The fireside chat will be made available for on-demand listening beginning Tuesday, March 9, 2021 at 7:00 a.m. EST. The webcast of the fireside chat will be available on the “Media” section of the Comp

Verastem Oncology to Participate in the H.C. Wainwright Global Life Sciences Conference

The biotech's chief medical officer has stepped down just two weeks after joining the company.

Why Verastem Stock Sank Today

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the departure of the Company's Chief Medical Officer, Frank Neumann, M.D., Ph.D., effective immediately. Dr. Neumann has left to accept a position at another Company. “Our team is making significant advances in achieving the Company's strategic goals, including maximizing the broad potential of our

Frank Neumann, M.D., Ph.D., to Depart Verastem Oncology

News for Verastem Stock (VSTM)